Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
By Georgina V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, J. Grob and 24 more. The Lancet, 2015
1,267 citations recorded by the source corpus.
Subfields: Computational Theory and Mathematics, Molecular Biology, Organic Chemistry
View Paper: https://www.semanticscholar.org/paper/304b0aa96b7315ce1bf15f4a653a28a03f2bd04b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- O. Michielin
- A. V. Akkooi
- R. Scolyer
- J. Gershenwald
- R. Dummer
- U. Keilholz
- A. Eggermont
- John F. Thompson
Citations in the corpus
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “0 months median PFS reported in COMBI-d [68] .”
- Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, methodology): “as well as stratification and analysis, are often based on the presence/absence of CNS disease.(6-20,73,74) Therefore, this additional level of granularity in the M category “maps” bet-”